Regulatory glossary

What Is a Complete Response Letter? FDA CRLs Explained

A Complete Response Letter (CRL) is the letter FDA sends when it has finished reviewing an application and decided not to approve it in its present form. It is issued under 21 CFR 314.110 for drugs and 21 CFR 601.3 for biologics, and it lists every deficiency the agency has identified, so the sponsor knows what has to be fixed before the application can be approved.

A CRL is not a rejection. It is closer to a work order: FDA is telling you, in writing, what it needs. Most of the work that follows is documentation you already have to assemble and defend.

What a CRL is, and what it isn't

Before 2008, FDA closed a review cycle with an "approvable" or "not approvable" letter. Both were replaced by the single Complete Response Letter so that every unapproved application ends the cycle the same way, with a complete list of deficiencies rather than a graded verdict.

Three things a CRL is commonly mistaken for:

• It is not a final decision. The application stays alive. You have a defined path back.
• It is not a public rebuke. Historically CRLs were confidential between FDA and the sponsor. That changed recently, and is covered below.
• It is not necessarily about your clinical data. In practice a large share of CRLs turn on manufacturing and facility issues rather than whether the drug works.

What a Complete Response Letter contains

A CRL describes the specific deficiencies FDA has identified and, where the agency can, recommends what would be needed to address them. Letters typically run to several pages; across the letters FDA has now published, the average is roughly 10,500 characters.

The deficiencies generally fall into a handful of families:

• Facility and inspection — an unsatisfactory pre-approval inspection, or an inspection that could not be completed. This can involve a contract manufacturer's site rather than your own.
• Product quality and CMC — impurities, stability data that does not support the proposed shelf life, specifications that are not justified, incomplete process or analytical method validation.
• Clinical efficacy — the evidence does not meet the substantial-evidence standard, or a single trial is being asked to carry more weight than it can.
• Safety — an unresolved signal, insufficient exposure, or a risk-benefit case the review division does not accept.
• Labeling — proposed labeling that does not match what the data support.
• Device and delivery — for combination products, human factors or delivery system issues.

An analysis by The FDA Group of 89 published CRLs found that 56% contained facility-inspection-related approvability issues and 41% cited product-quality problems such as impurities or failed stability testing. Manufacturing, not efficacy, is the most common reason an application does not get approved on the first cycle.

Your three options after a CRL

Under 21 CFR 314.110, an applicant who receives a Complete Response Letter must do one of three things:

1. Resubmit, providing everything needed to fully address all deficiencies identified in the letter.
2. Withdraw the application.
3. Request an opportunity for a hearing on whether there are grounds to deny approval.

The one-year clock

If you do none of the three within one year of the CRL being issued, FDA may treat that silence as a request to withdraw the application. You can avoid this by requesting an extension, and the regulation says FDA will grant any reasonable request for one.

If FDA does decide to treat your inaction as a withdrawal, it notifies you in writing, and you then have 30 days from that notification to explain why the application should not be withdrawn and to request more time.

Class 1 and Class 2 resubmissions

When you resubmit, FDA classifies the resubmission, and the class sets the review clock under the PDUFA performance goals:

The classification is FDA's call, not yours. If the agency decides a resubmission you filed as Class 1 actually contains Class 2 material, it can reclassify it and the clock resets to six months. Getting the scope wrong is one of the more expensive avoidable mistakes in a second cycle.

FDA now publishes Complete Response Letters

CRLs used to stay between FDA and the sponsor. In 2025 the agency began releasing them: a first batch of roughly 200 letters in the summer, followed by a further 89, with a stated commitment to publish CRLs promptly after they are issued.

They are available through the openFDA transparency API and a browsable table at open.fda.gov/crltable.

As of FDA's 13 August 2026 update, the dataset holds 445 Complete Response Letters, spanning letters issued between 2002 and 2026. The busiest year in the set is 2024, with 69 letters.

One trap if you analyse this dataset

Each record carries an approval_status field describing where that application stands today, and it is tempting to compute a first-cycle failure rate from it. Don't. The field splits almost perfectly along the release batches:

That is not a collapse in approval rates. The earlier releases covered CRLs for products that went on to be approved, while the later release covered still-unapproved products. Any "percentage of CRLs that end in approval" drawn from this dataset is measuring FDA's publication choices, not industry outcomes.

Each letter also names a company_rep, the sponsor's regulatory contact, along with the reviewing division and the signing official.

How to respond to a CRL well

The letter is the specification. A good response reads as though someone mapped each deficiency to an owner, a document and a piece of evidence, and closed them one at a time.

• Answer every deficiency, individually. A resubmission that addresses four of five items is not a complete response, and the cycle does not restart in your favour.
• Decide the resubmission class deliberately. Scope the response, then check honestly whether it is Class 1 or Class 2. Filing optimistically does not make the review faster.
• Trace every claim to a source. The second cycle is where inconsistencies between your response, your original dossier and your prior commitments to FDA get found. If a number in the response contradicts what is in Module 3, it will surface.
• Request a Type A meeting if the path is unclear. Where a deficiency is ambiguous or you disagree on approach, a post-action meeting is cheaper than guessing and burning a six-month cycle.
• Check your own history. Prior correspondence, commitments and annual reports form a record the review division can see. Contradicting a previous commitment is a self-inflicted deficiency.